130 related articles for article (PubMed ID: 16989688)
21. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
[TBL] [Abstract][Full Text] [Related]
22. Lymphatic filariasis in Andhra Pradesh Paper Mill Colony, Rajahmundry, India after nine rounds of MDA programme.
Mukhopadhyay AK
J Vector Borne Dis; 2010 Mar; 47(1):55-7. PubMed ID: 20231775
[No Abstract] [Full Text] [Related]
23. Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).
Kumar A; Sachan P
Trop Biomed; 2014 Jun; 31(2):225-9. PubMed ID: 25134891
[TBL] [Abstract][Full Text] [Related]
24. Lymphatic filariasis elimination programme in India: progress and challenges.
Ramaiah KD
Trends Parasitol; 2009 Jan; 25(1):7-8. PubMed ID: 19008150
[No Abstract] [Full Text] [Related]
25. Participation in three consecutive mass drug administrations in Leogane, Haiti.
Mathieu E; Direny AN; de Rochars MB; Streit TG; Addiss DG; Lammie PJ
Trop Med Int Health; 2006 Jun; 11(6):862-8. PubMed ID: 16772008
[TBL] [Abstract][Full Text] [Related]
26. Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review.
Babu BV; Babu GR
Trans R Soc Trop Med Hyg; 2014 Sep; 108(9):538-49. PubMed ID: 24728444
[TBL] [Abstract][Full Text] [Related]
27. A rapid method to assess the coverage of the mass drug administration of diethylcarbamazine in the program to eliminate lymphatic filariasis in India.
Babu BV
Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):44-5. PubMed ID: 15906640
[TBL] [Abstract][Full Text] [Related]
28. Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations.
Sunish IP; Munirathinam A; Kalimuthu M; Ashok Kumar V; Tyagi BK
J Trop Pediatr; 2014 Jun; 60(3):245-8. PubMed ID: 24343822
[TBL] [Abstract][Full Text] [Related]
29. Lymphatic filariasis: constraints ahead.
Mishra CP; Singh N
Indian J Public Health; 2003; 47(1):27-30. PubMed ID: 14723292
[No Abstract] [Full Text] [Related]
30. Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis.
Ramaiah KD; Vijay Kumar KN; Ravi R; Das PK
Ann Trop Med Parasitol; 2005 Apr; 99(3):243-52. PubMed ID: 15829134
[TBL] [Abstract][Full Text] [Related]
31. Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India.
Vanamail P; Ramaiah KD; Subramanian S; Pani SP; Yuvaraj J; Das PK
Ann Trop Med Parasitol; 2005 Apr; 99(3):237-42. PubMed ID: 15829133
[TBL] [Abstract][Full Text] [Related]
32. Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection.
Shenoy RK; Suma TK; Kumaraswami V; Rahmah N; Dhananjayan G; Padma S
Ann Trop Med Parasitol; 2009 Apr; 103(3):235-47. PubMed ID: 19341538
[TBL] [Abstract][Full Text] [Related]
33. Clinicians' practices related to management of filarial adenolymphangitis and lymphoedema in Orissa, India.
Kerketta AS; Babu BV; Swain BK
Acta Trop; 2007 Jun; 102(3):159-64. PubMed ID: 17553441
[TBL] [Abstract][Full Text] [Related]
34. Elimination of lymphatic filariasis in India.
Sabesan S; Ravi R; Das PK
Lancet Infect Dis; 2005 Jan; 5(1):4-5. PubMed ID: 15620551
[No Abstract] [Full Text] [Related]
35. Preventing confusion about side effects in a campaign to eliminate lymphatic filariasis.
Ramaiah KD; Ravi R; Das PK
Trends Parasitol; 2005 Jul; 21(7):307-8. PubMed ID: 15923141
[No Abstract] [Full Text] [Related]
36. Evidence for the use of albendazole for the elimination of lymphatic filariasis.
Sunish IP; Rajendran R; Mani TR; Dash AP; Tyagi BK
Lancet Infect Dis; 2006 Mar; 6(3):125-6. PubMed ID: 16500593
[No Abstract] [Full Text] [Related]
37. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
[TBL] [Abstract][Full Text] [Related]
38. Urban lymphatic filariasis in the city of Tanga, Tanzania, after seven rounds of mass drug administration.
Mwakitalu ME; Malecela MN; Pedersen EM; Mosha FW; Simonsen PE
Acta Trop; 2013 Dec; 128(3):692-700. PubMed ID: 24135628
[TBL] [Abstract][Full Text] [Related]
39. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India.
Mukhopadhyay AK; Patnaik SK; Satya Babu P; Rao KN
J Vector Borne Dis; 2008 Mar; 45(1):73-5. PubMed ID: 18399322
[No Abstract] [Full Text] [Related]
40. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka.
Gunawardena S; Sri Ranganathan S; Fernandopulle R
Trop Med Int Health; 2008 Sep; 13(9):1153-8. PubMed ID: 18631319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
